HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Tempest Therapeutics (NASDAQ:TPST) and maintained a price target of $47.
June 20, 2024 | 3:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Tempest Therapeutics (NASDAQ:TPST) and maintained a price target of $47.
The reiteration of a Buy rating and the maintenance of a $47 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100